News Focus
News Focus
icon url

jq1234

03/27/15 5:45 PM

#189283 RE: DewDiligence #189282

If OCRX's oral version can low AL similar to IV in acute setting, it could compete against Ravicti in maintenance and chronic setting of HE as Ravicti didn't work well with patients who took Xifaxan based on ph2 trial:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4237123/pdf/hep0059-1073.pdf

icon url

DewDiligence

03/30/15 8:53 AM

#189338 RE: DewDiligence #189282

HZNP acquires HPTX for $46/sh in cash—an 8% premium to Friday’s close:

http://finance.yahoo.com/news/horizon-pharma-plc-acquire-hyperion-100000624.html

The nominal deal value of $1.1B.

CC today at 8am ET.